U.S. markets closed

Psychemedics Corporation (PMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.0600+0.0350 (+1.16%)
At close: 03:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close3.0250
Bid2.5400 x 1100
Ask3.5000 x 900
Day's Range3.0500 - 3.4413
52 Week Range2.0600 - 6.7500
Avg. Volume13,261
Market Cap17.753M
Beta (5Y Monthly)0.68
PE Ratio (TTM)N/A
EPS (TTM)-0.6800
Earnings DateMar 19, 2024 - Mar 25, 2024
Forward Dividend & Yield0.28 (8.81%)
Ex-Dividend DateMay 24, 2023
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PMD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Psychemedics Corporation
    Daily – Vickers Top Insider Picks for 02/09/2024The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    13 days agoArgus Research
View more
  • GlobeNewswire

    Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas

    ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering exceptional service and maintaining the highest standards in hair drug testing. The move to Dallas underscores Psychemedics’ commitment to expanding operations, fostering innovation, and better serving its di

  • GlobeNewswire

    Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance

    ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she wil

  • GlobeNewswire

    Psychemedics Corporation Reports Third Quarter 2023 Financial Results

    ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company’s revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net lo